Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002528 | 0.81 | CYP2A6 (0.50) | CYP2A6ALDH1A1SMN1; SMN2NCOA3 | |
| SCHEMBL96527 | 0.72 | CYP2A6 (0.48) | CYP2A6ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL30940059 | 0.72 | CYP2A6 (0.53) | CYP2A6ALDH1A1RAB9ASMN1; SMN2NCOA3 | |
| SCHEMBL3962397 | 0.72 | CYP2A6 (0.53) | CYP2A6ALDH1A1RAB9ASMN1; SMN2NCOA3 | |
| SCHEMBL31167180 | 0.71 | CYP2A6 (0.56) | CYP2A6ALDH1A1 | |
| SCHEMBL1006461 | 0.71 | CYP2A6 (0.56) | CYP2A6ALDH1A1 | |
| SCHEMBL14438020 | 0.71 | CYP2A6 (0.51) | CYP2A6ALDH1A1RAB9ASMN1; SMN2CYP19A1 | |
| SCHEMBL28913407 | 0.71 | CYP2A6 (0.51) | CYP2A6ALDH1A1RAB9ASMN1; SMN2NCOA3 | |
| SCHEMBL194930 | 0.70 | CYP2A6 (0.56) | CYP2A6ALDH1A1RAB9ASMN1; SMN2NCOA3 | |
| SCHEMBL10285458 | 0.70 | CYP2A6 (0.47) | CYP2A6ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| EP-2963019-B1 | METHOD FOR PRODUCING PYRIDINE-3-SULFONYL CHLORIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3241826-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10370357-B2 | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-6294536-B1 | CONTROL OF PROTOZOA AND REDUCTION IN THE INCIDENCE OF ASSOCIATED DISEASES AND DEATH AND CONSEQUENT IMPROVEMENT IN RETARDED GROWTH AND GENERAL CONDITION AND PREVENTING DECREASE GROWTH AND GENERAL CONDITION | TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K. (JP) | 2001-09-25 | — | — | US | disclosed |
| WO-1999011634-A1 | TRIAZINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-11 | — | — | WO | disclosed |
| WO-1997011075-A1 | TRIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| EP-0305939-B1 | Process of producing sulfonylurea derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4994571-A | Reacting heterocycle-containing sulfonamide compound with carbonyl compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0305939-A1 | Process of producing sulfonylurea derivatives | Takeda Chemical Industries, Ltd. (JP) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CYP2A6 46/4885ALDH1A1 1184/4885RAB9A 1700/4885 |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CYP2A6 46/4885ALDH1A1 1184/4885RAB9A 1700/4885 |
| US-10370357-B2 | Method for producing sulfonyl chloride compound | P2RY4, P2RY6, P2RX4 | CYP2A6 70/4885ALDH1A1 2395/4885RAB9A 3035/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | CYP2A6 1525/4885ALDH1A1 1043/4885RAB9A 824/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CYP2A6 46/4885ALDH1A1 1184/4885RAB9A 1700/4885 |
| US-10844011-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | CYP2A6 46/4885ALDH1A1 1184/4885RAB9A 1700/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | CYP2A6 406/4885ALDH1A1 795/4885RAB9A 2206/4885 |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | PGA5, ATP6AP1, PPA1 | CYP2A6 256/4885ALDH1A1 1988/4885RAB9A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.